Is MiMedx Group, Inc. overvalued or undervalued?

As of 21 November 2025, the valuation grade for MiMedx Group, Inc. moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 24, an EV to EBITDA of 14.64, and a Price to Book Value of 4.75. In comparison to its peers, LeMaitre Vascular, Inc. has a higher P/E of 49.77 and an EV to EBITDA of 33.90, while Alphatec Holdings, Inc. shows a negative P/E, highlighting the variability in valuations within the sector.
Despite the fair valuation, MiMedx has underperformed relative to the S&P 500, particularly on a year-to-date basis with a return of -29.73% compared to the index's 12.26%. This underperformance, alongside its current valuation metrics, suggests that while the stock is fairly valued, it may face challenges in regaining momentum in the near term.